Cannabis Based Medicines Gain Traction as Research & Development Ramp up - Company Looks to Develop Topical Cannabis Medicine to Treat Skin Cancer

CORAL SPRINGS, Florida, May 15, 2014 /PRNewswire/ --

Marijuana industry displays versatility as companies diversify products by specializing in developing Cannabis Based medicines: New Colombia Resources, Inc. (OTC: NEWC), Easton Pharmaceuticals Inc. (OTC: EAPH), GW Pharmaceuticals plc (NASDAQ: GWPH), Medical Marijuana, Inc. (OTC: MJNA) and Terra Tech Corp. (OTC: TRTC)

New Colombia Resources, Inc. (OTCQB: NEWC), a U.S. company with coal and other resource assets in Colombia, is pleased to announce an agreement of collaboration with Farmatech S.A., of Medellin, Colombia, for the research and development of topical cannabis based medicines to treat skin cancer and other ailments in Colombia.  Farmatech S.A. is a pharmaceutical laboratory that collaborates with private companies, universities, institutions, and NGOs. Their mission is to manufacture medicines as well as cosmetic and veterinary products, both proprietary and by contract. New Colombia Resources is in discussions with Cannabis Science, Inc. (OTCQB: CBIS) to oversee research in Colombia once the protocols are established by Farmatech S.A.

To read the full press release, please click here: http://www.fnmprofiles.com/profiles-newc.html

Farmatech S.A. is GMP certified by INVIMA (National Institute of Food & Drug Vigilance) for the production of the following dosage formulations:  Solids: Tablets with or without cover, hard gelatin capsules, lozenges, effervescent powders and granules; Semisolid: creams, gels and ointments; Bulk manufacture of suppositories;  Liquid solutions, emulsions, and suspensions; and Non lactic antibiotics: Solid powder.  In association with Dr. Robert Melamede PhD, President of Cannabis Science Inc., New Colombia will work with Farmatech S.A. to develop products using formulations and processes specific to the ailment being treated. For more information on Farmatech S.A., visit http://www.farmatech.com.

Easton Pharmaceuticals Inc. (OTC Pink: EAPH) recently announced it had provided BMV Medica S.A. de C.V. confirmation of final payment to BMV towards it Mexican initiatives regarding Easton's Viorra product. Announces new Michigan proposal in its medical marijuana initiatives. As previously disclosed, Easton has engaged and announced that BMV Medica S.A. de C.V. has been appointed as its sole exclusive distributor in Mexico. BMV has signed an agreement with Easton on utilizing its resources and relationships aimed at marketing Viorra successfully in a market that BMV believes can be positioned as a leading-edge daily-use woman's health product to also assist in the treatment of FSAD type conditions. Easton has given BMV its approval to launch certain initiatives once manufacturing has been set up in Mexico, currently being addressed by BMV, which when complete, could also supply the United States, Canadian and International markets.

GW  Pharmaceuticals plc (NASDAQ: GWPH) recently announced that the Company has received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug application (IND) is now open for Epidiolex in the treatment of Dravet Syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. GW expects to commence a Phase 2/3 clinical trial in the second half of 2014. Epidiolex has already received orphan drug designation from the FDA for the treatment of Dravet syndrome. "The acceptance of this IND by the FDA is a significant milestone for Epidiolex and for children with Dravet syndrome for whom existing anti-epileptic medicines often do not provide adequate relief," stated Justin Gover, GW's Chief Executive Officer. "This journey began with requests from the U.S. epilepsy physician and patient community to utilize Epidiolex and has now led to GW embarking on its own formal development program with a view to seeking market authorization from the FDA as rapidly as possible. We are committed to providing a prescription cannabidiol (CBD) medicine for children with Dravet syndrome who have exhausted all other therapeutic options."

Medical Marijuana, Inc. (OTC: MJNA) recently announce that executives from two of its subsidiaries have been recognized as Board of Director nominees by the National Cannabis Industry Association (NCIA). Michael Roberts, Chief Executive Officer of Wellness Managed Services' new company, MPS International (MPSI) and HempMeds(TM) board member, Michael Julian, are both running for election. Online voting is open to NCIA member companies through May 16th at midnight. "The founders of our country, who crafted one of the only constitutions in world history that hasn't been re-written, grew, sold, bought and traded hemp (cannabis) products," states Michael Julian. "Through decades of propaganda, one of the cannabis plants, 'marijuana' has since been added to the list of Schedule I controlled substances. Our legislators are beginning to see just how foolish this is, but more can and should immediately be done to make cannabis ('marijuana' and hemp) completely legal for growth and cultivation in the U.S."

Terra Tech Corp.'s (OTCQB: TRTC) subsidiary, MediFarm LLC, announced it has completed filings for the special use permit process for medical marijuana licensing in unincorporated Clark County, Nevada. In addition, on April 22, 2014, MediFarm LLC filed requisite information with the Clark County Department of Business Licensing for four medical marijuana applications; two Dispensaries, one Cultivation Facility and one Production Facility. MediFarm representatives recently met with the Clark County planning department to file Land Use applications as part of the special use permit process in unincorporated Clark County. The company anticipates that Clark County Commissioners will hear applications for these special use permits on June 5th. "This initial process in Clark County was a tremendous undertaking for our team," explains Derek Peterson, CEO Terra Tech Corp. "As a byproduct of this process we are left with a great base to build our state level applications from. We feel well positioned to submit to the state in a timely manner should we make it through the county's review process. In addition we are focusing on other counties throughout the state."

FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter:  http://twitter.com/FNMgroup. 

DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG was not compensated for this New Colombia Resources, Inc. news coverage but expects to be compensated in the future which will be fully disclosed at that time. FNMG HOLDS NO SHARES OF New Colombia Resources, Inc.

FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.  

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company: FN Media Group, LLC
Contact email: editor@financialnewsmedia.com
U.S. Phone: +1(954)345-0611
URL: http://www.financialnewsmedia.com

 

SOURCE FN Media Group, LLC




Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.